1. Pink Sheet
  2. >>Geography

EU Produces Guide On 'Challenges' To NASH Drug Development

 
• By Ian Schofield

Regulatory experience with the development of new medicines for non-alcoholic steatohepatitis is limited, and because of the high unmet need, a conditional marketing authorization approach should be considered, the European Medicines Agency says.

Hand holding a luminated liver shape
Treating fatty liver conditions is the focus of a new EU reflection paper • Source: Shutterstock

The European Medicines Agency has published a “reflection paper” on the regulatory requirements for new medicines for non-alcoholic steatohepatitis (NASH) in view of what it calls the “major challenges” to drug development caused by the specific characteristics of the disease.

The paper, which was published on 4 April and comes into effect on 1 October, provides a high-level description of the requirements for drug development in this field. “Due...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography